Smaller Peptide Inhibitors Designed to Target the 'Undruggable' Cancer Protein β-Catenin
Researchers designed novel bicyclic helical peptides that bind the flat, cavity-lacking surface of the oncogene β-catenin with high affinity, achieving single-digit micromolar activity in cell-based assays.
Quick Facts
What This Study Found
A bicyclic stitched peptide with unprecedented crosslink architecture was designed to bind β-catenin, with the binding mode confirmed by crystal structure and cell-based activity reaching single-digit micromolar inhibition.
Key Numbers
The bicyclic peptides are considerably smaller than previous β-catenin inhibitors while maintaining high binding affinity.
How They Did This
Structure-based design starting from the Axin α-helical binding motif, followed by sequence maturation, bicyclization with novel crosslink architecture, X-ray crystallography to confirm binding, and cell-based assay validation.
Why This Research Matters
β-catenin is implicated in colorectal, breast, liver, and many other cancers but has resisted drug development for decades. These smaller peptide inhibitors represent a potential breakthrough for targeting this challenging oncogene.
The Bigger Picture
Many cancer-driving proteins have flat surfaces that resist conventional drug design. Constrained peptides — like the bicyclic helical structures developed here — represent a growing toolbox for tackling these 'undruggable' targets, potentially opening new therapeutic avenues across oncology.
What This Study Doesn't Tell Us
Early-stage drug design — demonstrated binding and cell-based activity but no in vivo testing. Cell penetration and metabolic stability need further optimization. Single-digit micromolar potency may need improvement for therapeutic use.
Questions This Raises
- ?Can these bicyclic peptides be further optimized for nanomolar potency and oral bioavailability?
- ?Would they be effective in animal cancer models with activated Wnt/β-catenin signaling?
- ?Could this stitched peptide design approach be applied to other flat protein-protein interaction surfaces in cancer?
Trust & Context
- Key Stat:
- Single-digit μM activity Bicyclic peptide inhibitor achieves cell-based activity against the notoriously difficult cancer target β-catenin
- Evidence Grade:
- Preliminary evidence — proof-of-concept drug design study with in vitro and cell-based validation but no animal testing.
- Study Age:
- Published in 2024, representing the cutting edge of constrained peptide drug design for cancer targets.
- Original Title:
- Structure-Based Design of Bicyclic Helical Peptides That Target the Oncogene β-Catenin.
- Published In:
- Angewandte Chemie (International ed. in English), 63(47), e202411749 (2024)
- Authors:
- Yeste-Vázquez, Alejandro, Paulussen, Felix M, Wendt, Mathias, Klintrot, Rasmus, Schulte, Clemens, Wallraven, Kerstin, van Gijzel, Lieke, Simeonov, Boris, van der Gaag, Maurice, Gerber, Alan, Maric, Hans M, Hennig, Sven, Grossmann, Tom N
- Database ID:
- RPEP-09602
Evidence Hierarchy
Frequently Asked Questions
Why is β-catenin so hard to target with drugs?
Unlike most drug targets, β-catenin has a flat, smooth protein surface without deep pockets for small molecules to bind in. The protein-protein interaction surface is large and featureless, making it one of the most challenging targets in cancer drug development.
What makes these peptides different from previous β-catenin inhibitors?
Previous inhibitors were large, high-molecular-weight molecules. These bicyclic peptides are considerably smaller while maintaining high binding affinity, thanks to a novel stitched architecture that locks them into the helical shape needed to bind β-catenin's flat surface.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09602APA
Yeste-Vázquez, Alejandro; Paulussen, Felix M; Wendt, Mathias; Klintrot, Rasmus; Schulte, Clemens; Wallraven, Kerstin; van Gijzel, Lieke; Simeonov, Boris; van der Gaag, Maurice; Gerber, Alan; Maric, Hans M; Hennig, Sven; Grossmann, Tom N. (2024). Structure-Based Design of Bicyclic Helical Peptides That Target the Oncogene β-Catenin.. Angewandte Chemie (International ed. in English), 63(47), e202411749. https://doi.org/10.1002/anie.202411749
MLA
Yeste-Vázquez, Alejandro, et al. "Structure-Based Design of Bicyclic Helical Peptides That Target the Oncogene β-Catenin.." Angewandte Chemie (International ed. in English), 2024. https://doi.org/10.1002/anie.202411749
RethinkPeptides
RethinkPeptides Research Database. "Structure-Based Design of Bicyclic Helical Peptides That Tar..." RPEP-09602. Retrieved from https://rethinkpeptides.com/research/yeste-vazquez-2024-structurebased-design-of-bicyclic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.